Zimhi (naloxone hydrochloride) injection is now available for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Zimhi is an opioid antagonist that delivers 5mg/0.5mL naloxone hydrochloride solution in a single-dose, prefilled syringe for intramuscular or subcutaneous use. The product is intended for immediate administration as emergency therapy in settings where opioids may be present.

“Zimhi provides the highest intramuscular dose of naloxone among naloxone injection devices currently available,” said Dr Dennis J. Carlo, President and CEO of Adamis. “We believe that Zimhi will play a pivotal role in the treatment of opioid overdose, while contributing positively to the entire community that has been impacted by the opioid epidemic.”

Zimhi is intended to be administered by individuals 12 years of age and older; those with limited hand strength may find use of the device difficult. Each Zimhi device contains a single dose of naloxone hydrochloride for single-dose injection. Repeat doses may be administered as necessary using a new Zimhi device.

The Company is offering a copay program for eligible patients. Discounted public interest pricing is also available for first responders and community health organizations.

Reference

US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product. News release. Adamis Pharmaceuticals Corporation. Accessed April 1, 2022. https://www.globenewswire.com/news-release/2022/03/31/2414388/32832/en/US-WorldMeds-and-Adamis-Pharmaceuticals-Announce-U-S-Launch-of-ZIMHI-Naloxone-Product.html